Geode Capital Management Portfolio holdings
Geode Capital Management, founded in 2001 and based in Boston, Massachusetts, is a prominent institutional asset management firm known for its expertise in low-cost, systematic index investing. Originally established to manage internal index funds for Fidelity Investments, Geode became an independent entity while retaining a close relationship with Fidelity, focusing on passive investment strategies that track major market indices. The firm oversees hundreds of billions in assets, offering a range of mutual funds and separately managed accounts primarily for institutional clients, such as pension funds and endowments, with an emphasis on minimizing costs and maximizing efficiency. Geode’s disciplined, quantitative approach and avoidance of active management have made it a key player in the rise of index-based investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$1.18B |
| 2 |
Apple
AAPL
|
+$1.11B |
| 3 |
Broadcom
AVGO
|
+$562M |
| 4 |
Amazon
AMZN
|
+$553M |
| 5 |
Palo Alto Networks
PANW
|
+$485M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$246M |
| 2 |
O'Reilly Automotive
ORLY
|
+$149M |
| 3 |
Cadence Design Systems
CDNS
|
+$149M |
| 4 |
Synopsys
SNPS
|
+$134M |
| 5 |
Chipotle Mexican Grill
CMG
|
+$125M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.24% |
| 2 | Healthcare | 13.33% |
| 3 | Financials | 12.09% |
| 4 | Consumer Discretionary | 10.85% |
| 5 | Industrials | 9.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3226
INmune Bio
INMB
$46.5M
| $1.4M | ﹤0.01% |
154,680
+11,023
| +8% | +$88.5K |
|
3227
Atossa Therapeutics
ATOS
$20.6M
| $1.4M | ﹤0.01% |
74,174
-6,552
| -8% | -$79.5K |
|
3228
Century Therapeutics
IPSC
$364M
| $1.4M | ﹤0.01% |
443,499
+22,322
| +5% | +$72K |
|
3229
Puma Biotechnology
PBYI
$404M
| $1.4M | ﹤0.01% |
396,396
+4,774
| +1% | +$14.9K |
|
3230
Saga Communications
SGA
$57M
| $1.4M | ﹤0.01% |
65,455
+12,668
| +24% | +$272K |
|
|
SEEL
3231
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
| $1.39M | ﹤0.01% |
304
+8
| +3% | +$27.8K |
|
3232
Hurco Companies Inc
HURC
$135M
| $1.37M | ﹤0.01% |
63,496
+5,376
| +9% | +$122K |
|
|
RDNW
3233
RideNow Group
RDNW
$238M
| $1.37M | ﹤0.01% |
111,134
-102,790
| -48% | -$959K |
|
3234
Foster
FSTR
$430M
| $1.37M | ﹤0.01% |
96,093
+582
| +0.6% | +$7.17K |
|
3235
Black Diamond Therapeutics
BDTX
$96.8M
| $1.37M | ﹤0.01% |
271,207
+779
| +0.3% | +$1.59K |
|
|
PVBC
3236
DELISTED
Provident Bancorp
PVBC
| $1.37M | ﹤0.01% |
165,264
-130,333
| -44% | -$983K |
|
3237
AXT Inc
AXTI
$3.95B
| $1.37M | ﹤0.01% |
397,707
-400,253
| -50% | -$1.35M |
|
|
LTCH
3238
DELISTED
Latch, Inc. Common Stock
LTCH
| $1.37M | ﹤0.01% |
984,252
-986,479
| -50% | -$922K |
|
3239
Orchestra BioMed
OBIO
$238M
| $1.36M | ﹤0.01% |
194,756
+69,750
| +56% | +$1.06M |
|
|
LENZ
3240
LENZ Therapeutics
LENZ
$166M
| $1.35M | ﹤0.01% |
74,024
+38,684
| +109% | +$773K |
|
|
KC
3241
Kingsoft Cloud Holdings
KC
$3.34B
| $1.34M | ﹤0.01% |
219,466
-46,798
| -18% | -$279K |
|
|
SWKH
3242
DELISTED
SWK Holdings
SWKH
| $1.34M | ﹤0.01% |
100,685
+2,245
| +2% | +$30.8K |
|
3243
Equinor
EQNR
$97.7B
| $1.34M | ﹤0.01% |
45,714
| – | – |
|
3244
Cytosorbents Corp
CTSO
$22.7M
| $1.33M | ﹤0.01% |
371,708
| – | – |
|
3245
Standard BioTools
LAB
$340M
| $1.33M | ﹤0.01% |
687,946
-26,101
| -4% | -$51.5K |
|
3246
Stratasys
SSYS
$679M
| $1.33M | ﹤0.01% |
74,745
+6,862
| +10% | +$107K |
|
|
AVDL
3247
DELISTED
Avadel Pharmaceuticals
AVDL
| $1.33M | ﹤0.01% |
80,402
+399
| +0.5% | +$5.19K |
|
|
DFTX
3248
Definium Therapeutics
DFTX
$5.78B
| $1.32M | ﹤0.01% |
371,010
+30,955
| +9% | +$107K |
|
3249
Jasper Therapeutics
JSPR
$21M
| $1.32M | ﹤0.01% |
96,550
-10,481
| -10% | -$156K |
|
3250
ReposiTrak
TRAK
$153M
| $1.32M | ﹤0.01% |
131,080
+16,374
| +14% | +$123K |
|
Similar funds
Geode Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, Geode Capital Management held 4,889 positions worth $851B, up 11% from $770B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Trading was light in Q2 2023: portfolio turnover was 4.4%. Geode Capital Management opened 83 new positions and exited 132, leaving the 4,889-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 26% a quarter earlier, followed by Healthcare and Financials.
- Geode Capital Management's largest Q2 2023 buy was Coupang: 4,567,454 shares worth $79.5M.
- Geode Capital Management added most to Microsoft in Q2 2023, an estimated $1.18B increase.
- Geode Capital Management's biggest Q2 2023 reduction was Procter & Gamble, cutting an estimated $246M.
- Geode Capital Management fully exited Evoqua Water Technologies Corp. Common Stock in Q2 2023, selling an estimated $111M.
- Geode Capital Management's ten largest holdings make up 26% of its $851B portfolio in Q2 2023.
- Geode Capital Management opened 83 new positions and closed 132 in Q2 2023.
- Geode Capital Management's portfolio value rose 11% quarter-over-quarter to $851B.
Based on Geode Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.